The global glaucoma market size accounted for USD 8.99 billion in 2024, grew to USD 9.41 billion in 2025 and is expected to be worth around USD 14.23 billion by 2034, registering a CAGR of 4.7% between 2024 and 2034. The North America glaucoma market size is calculated at USD 3.51 billion in 2024 and is estimated to grow at a CAGR of 4.83% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Glaucoma Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Glaucoma Market, by Disease Type, 2024-2034
8.1.1 Open Angle Glaucoma
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Angle Closure Glaucoma
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Other
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Glaucoma Market, by Drug Class, 2024-2034
9.1.1. Prostaglandin Analog
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Beta Blockers
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Adrenergic Agonist
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Carbonic Anhydrase Inhibitors
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Glaucoma Market, by Distribution Channel, 2024-2034
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1. Novartis
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Santen Pharmaceutical
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. New World Medical
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Ellex Medical Lasers
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Abbott Laboratories
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Johnson & Johnson
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Ziemer Ophthalmic SystemsTopcon
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Lumenis
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Allergan
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample